

May 6, 2021

To,
The Corporate Relations Department
The BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001.
Ref:- Scrip Code:- 500126

To,
The Listing Department
The National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (East),
Mumbai – 400051
Ref:- Symbol:- PGHL

Dear Sir / Madam,

Sub:- Unaudited Financial Results for the quarter ended March 31, 2021

We are pleased to inform you that at the meeting of the Board of Directors of the Company held today, the Unaudited Financial Results for the quarter ended March 31, 2021 were approved.

We are enclosing herewith the following:

- a. Unaudited Financial Results for the quarter ended March 31, 2021;
- b. Press Release; and
- c. Limited Review Report in respect of the Unaudited Financial Results for the quarter ended March 31, 2021 furnished by Statutory Auditors of the Company

Kindly take the same on record and oblige.

Thanking you,
Yours faithfully,

For Procter & Gamble Health Limited

MILIND VASANT THATTE
Digitally signed
by MILIND
VASANT THATTE
Date: 2021.05.06
17:34:42 +05'30'

Milind Thatte
Managing Director

PROCTER & GAMBLE HEALTH LIMITED

Regd. Office: Godrej One, 8th Floor, Eastern Express Highway, Pirojshanagar, Vikhroli (East), Mumbai : 400 079.

CIN No. L99999MH1967PLC013726, email: investor@procterandgamble.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 MARCH 2021

(₹ in lakhs)

Sr. No.	Particulars	(1)	(2)	(3)	(4)	(5)	(6)
		Three months ended 31st March 2021	Preceding Three months ended 31st December 2020	Corresponding Three months ended 31st March 2020	Nine Months ended 31st March 2021	Nine months ended 31st March 2020 [Refer note 6]	Eighteen months ended 30th June 2020
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1.	Revenue from Operations	21,915.0	24,022.0	22,810.6	72,334.0	69,004.0	1,35,586.0
2.	Other Income	324.0	572.0	1,026.3	1,568.0	2,304.4	6,889.0
3.	Total Income (1+2)	22,239.0	24,594.0	23,836.9	73,902.0	71,308.4	1,42,475.0
4.	Expenses						
	a) Cost of materials consumed	7,750.0	4,667.0	6,484.1	21,722.0	20,216.6	41,609.6
	b) Purchases of stock-in-trade	360.0	426.0	734.5	1,302.0	1,650.1	2,837.4
	c) Changes in inventories of finished goods, work-in-progress and stock in trade	(1,432.0)	1,265.0	799.8	(492.0)	1,968.6	(1,303.0)
	d) Employee benefits expense	3,754.5	3,090.2	2,315.5	10,659.0	8,365.8	18,293.0
	e) Depreciation and amortisation expense	767.0	785.0	423.8	2,288.0	1,257.1	2,945.0
	f) Finance Costs	20.0	19.0	-	63.0	-	-
	g) Other expenses	8,409.5	5,698.8	6,602.8	19,385.0	21,036.7	42,608.0
	Total expenses (4)	19,629.0	15,951.0	17,360.5	54,927.0	54,494.9	1,06,990.0
5.	Profit before exceptional items and tax (3-4)	2,610.0	8,643.0	6,476.4	18,975.0	16,813.5	35,485.0
6.	Less: Exceptional items	-	-	-	-	-	-
7.	Profit before tax (5-6)	2,610.0	8,643.0	6,476.4	18,975.0	16,813.5	35,485.0
8.	Tax expenses						
	Current Tax	850.0	2,154.0	1,539.1	5,038.0	3,736.6	10,278.0
	Deferred Tax	28.0	(48.0)	291.1	(113.0)	1,033.7	599.0
	Tax for earlier years	155.0	(251.0)	-	(241.0)	-	(800.0)
9.	Net Profit for the period (7-8)	1,577.0	6,788.0	4,646.2	14,291.0	12,043.2	25,408.0
10.	Other Comprehensive Income						
	Items that will not be reclassified to profit or loss						
	i. Re-measurement gains/(losses) on defined benefit plans	495.0	(963.0)	(727.9)	(495.0)	(827.9)	(1,237.0)
	ii. Income tax effect	(124.0)	242.0	183.2	125.0	198.7	311.0
	Total Other Comprehensive Income, net of tax	371.0	(721.0)	(544.7)	(370.0)	(629.2)	(926.0)
11.	Total Comprehensive Income for the period (9+10)	1,948.0	6,067.0	4,101.5	13,921.0	11,414.0	24,482.0
12.	Paid-up equity share capital (Face Value Rs 10/- each)	1,660.0	1,660.0	1,660.0	1,660.0	1,660.0	1,660.0
13.	Other equity excluding Revaluation reserve as per Balance sheet	-	-	-	-	-	88,974.0
14.	Earnings per equity share (of Rs 10/- each) *(not annualised)						
	(a) Basic and Diluted (in Rs.)	* 9.5	* 40.9	* 28	* 86.1	* 72.5	* 153.1

- Notes:
- The above financial results for the quarter and nine months ended March 31, 2021 have been reviewed and recommended by the Audit Committee, and approved by the Board of Directors of the Company at their Meeting held on May 6, 2021. The statutory auditors have carried out limited review of this unaudited financials results.
 - The unaudited financial results of the Company for the quarter and nine months ended March 31, 2021 have been prepared in accordance with Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standard) Rules, 2015, as amended.
 - As a result of the nationwide lockdown imposed by the Government of India in view of the Covid-19 pandemic, the operations of the Company were temporarily disrupted at its manufacturing, warehouse and distribution locations from second half of March 2020. The operations have gradually resumed in a phased manner in line with the Government directives issued from time to time. The Company's Management has evaluated the impact of this pandemic on its business operations and financial position and based on such review, there is no significant impact on the Company's assets, capital and financial resources, profitability parameters or liquidity positions as at March 31, 2021. The Management does not envisage any impact on the going concern assumption in the foreseeable future. However, the impact assessment of COVID-19 will be a continuing process given the uncertainties associated with its nature and duration.
 - Effective July 1, 2020, the Company has adopted Ind AS 116, Leases and applied the standard to its Leases using the modified retrospective approach. Accordingly, the Company has not restated comparative information. This has resulted in recognizing a lease liability measured at present value of the remaining lease payments and a corresponding Right-of-Use (ROU) asset as if the lease has been commenced w.e.f. 1st July 2020. The Company discounted remaining lease payments using the lessee's incremental borrowing rate as at 1st July 2020. The Company has also elected not to apply the requirements of Ind AS 116 to short term leases and leases for which underlying asset is of low value. In the results for the current period, the nature of expenses in respect of Operating lease has changed from lease rent in previous periods to depreciation cost for the right-of-use asset and finance cost for interest accrued on lease liability. The Company has therefore recognised a lease liability and a corresponding ROU asset as at 1st July 2020. The net impact of this adoption is not material on the results for the period and earning per share.
 - The Company now operates under only one segment i.e. Pharmaceuticals which is its continuing operations. Accordingly, no separate segment information has been provided.
 - Figures for the nine months ended March 31, 2020 are the balancing figures between the reported unaudited figures of the Fifteen months ended March 31, 2020 and six months ended June 30, 2019, which are presented in the unaudited financial result for the purpose of comparison with comparable period of current period year to date figures.
 - Previous period figures have been regrouped / reclassified wherever necessary.

For Procter & Gamble Health Limited

MILIND VASANT THATTE

Digitally signed by MILIND VASANT THATTE
Date: 2021.05.06 17:23:32 +05'30'

Milind Thatte
Managing Director
DIN No.08092990

Place : Mumbai
Date : 6 May 2021
Please visit us at our website www.pghealthindia.com



Procter & Gamble Health Limited Announces Third Quarter Results

Sales lower by 4% for quarter ended March 31, 2021

Mumbai, May 6, 2021: Procter & Gamble Health Limited announced today its financial results for the quarter ended March 31, 2021. The company has recorded sales of ₹ 214 crores down by 4% vs corresponding quarter of last year, impacted by stock challenges and higher last year base on account of exports sales phasing during the same quarter last year. Sales for nine months ending March 31, 2021 are ₹ 710 Crores, up by 5% vs nine months year ago. The Profit After Tax (PAT) is ₹ 15.8 crores vs ₹ 46.5 crores in the corresponding quarter last year, impacted by lower sales for the quarter and lower expense base last year supported by provision true ups and reversals. PAT for nine months ended March 31, 2021 is ₹ 142.9 crores vs ₹ 120.4 crores, up by 19% vs nine months period of last year.

Milind Thatte, Managing Director, Procter & Gamble Health Limited said, *“As the country and the entire healthcare ecosystem is faced with one of the most challenging circumstances in recent times, Procter & Gamble Health Limited stands committed to working with healthcare practitioners and distribution partners towards ensuring uninterrupted service and supplies of our medicines and nutraceutical products to patients and consumers across India. Amidst turbulent times, the Company delivered a total sale of ₹ 214 crores in the quarter ending March 31, 2021. While the quarter saw a decline of 4% vs last year, we will continue to ramp up to serve growing consumer demand backed by strong supply chain continuity plans.*

He further added, *“Our top priority continues to be the health and safety of our employees and partners, while supporting communities through relief efforts under our ‘SEHAT’ (meaning Health) CSR initiative and through ‘P&G Suraksha India’ Covid-19 relief program. As P&G group, we have pledged to donate INR 50 Cr towards 10 lakh vaccine doses for 5 lakh citizens in partnership with state governments and local authorities.”*

About Procter & Gamble Health Limited:

Procter & Gamble Health Limited is one of India’s largest VMS Companies manufacturing and marketing over-the-counter vitamins, minerals, and supplements products for a healthy lifestyle and improved quality of life, including Neurobion, Livogen, SevenSeas, Evion, Polybion and Nasivion. Please visit www.pghealthindia.com for the latest news and information about Procter & Gamble Health Limited and its brands.

About Procter & Gamble:

P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Ambi Pur®, Ariel®, Gillette®, Head & Shoulders®, Olay®, Oral-B®, Pampers®, Pantene®, Tide®, Vicks®, and Whisper®. The P&G community includes operations in approximately 70 countries worldwide.

CONTACTS

Media Contacts - Procter & Gamble Health Limited:

- Ruchita Mehra | mehra.r@pg.com
- Paromita Kundu | kundu.p.1@pg.com

Investor Relations Contact:

- Flavia Machado | machado.f.1@pg.com

Procter & Gamble Health Limited

(Formerly known as Merck Limited)

CIN: L99999MH1967PLC013726

Registered Office: Godrej One, 8th Floor,

Pirojshanagar, Eastern Express Highway, Vikhroli East,

Mumbai 400 079 | Tel: (91-22) 6866 9000

www.pghealthindia.com

HARIBHAKTI & CO. LLP

Chartered Accountants

Independent Auditor's Review Report on quarterly and year to date Unaudited Financial Results of Procter & Gamble Health Limited (formerly known as Merck Limited) pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

To the Board of Directors

Procter & Gamble Health Limited (formerly known as Merck Limited)

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **Procter & Gamble Health Limited** ("the Company") for the quarter ended March 31, 2021 and for the period from July 01, 2020 to March 31, 2021 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of the company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



Haribhakti & Co. LLP, Chartered Accountants Regn. No. AAC- 3768, a limited liability partnership registered in India (converted on 17th June, 2014 from a firm Haribhakti & Co. FRN: 103523W)
Registered offices: 705, Leela Business Park, Andheri-Kurla Road, Andheri (E), Mumbai - 400 059, India. Tel:+91 22 6672 9999 Fax:+91 22 6672 9777
Other offices: Ahmedabad, Bengaluru, Chennai, Coimbatore, Hyderabad, Kolkata, New Delhi, Pune.

HARIBHAKTI & CO. LLP

Chartered Accountants

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Haribhakti & Co. LLP

Chartered Accountants

ICAI Firm Registration No.103523W/W100048



Hemant J. Bhatt

Partner

Membership No.: 036834

UDIN: 21036834AAAAAR3556

Place: Mumbai

Date: May 06, 2021